Vor Biopharma

Recent news

• Company notice
  Vor Biopharma | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.
  SEC · 2026/4/22
• Rating change
  TD Cowen Maintains Vor Biopharma(VOR.US) With Buy Rating
  Market Newswire · 2026/5/14
• Wells Fargo Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $30
  Market Newswire · 2026/8/31
• Company notice
  Vor Biopharma | 4: Statement of changes in beneficial ownership of securities-10% Owner RA CAPITAL MANAGEMENT, L.P.
  SEC · 2026/10/6
• Wedbush Maintains Vor Biopharma(VOR.US) With Hold Rating, Raises Target Price to $27
  Market Newswire · 2026/8/12
• Rating change
  A Quick Look at Today's Ratings for Vor Biopharma(VOR.US), With a Forecast Between $15 to $40
  Market Newswire · 2026/3/31
• Rating change
  Wells Fargo Initiates Vor Biopharma(VOR.US) With Buy Rating, Announces Target Price $30
  Market Newswire · 2026/3/19
• Stifel Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $40
  Market Newswire · 2026/9/28
• Rating change
  Jefferies Initiates Vor Biopharma(VOR.US) With Buy Rating, Announces Target Price $50
  Market Newswire · 2026/3/30
• Jefferies Maintains Vor Biopharma(VOR.US) With Buy Rating, Cuts Target Price to $48
  Market Newswire · 2026/9/9
• Company notice
  Vor Biopharma | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.
  SEC · 2026/6/13
• Rating change
  HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $31 Price Target
  Benzinga · 2026/5/19
• Company notice
  Vor Biopharma | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.
  SEC · 2026/4/25
• Company notice
  Vor Biopharma | 4: Statement of changes in beneficial ownership of securities-10% Owner RA CAPITAL MANAGEMENT, L.P.
  SEC · 2026/7/22
• Rating change
  Citi Initiates Vor Biopharma(VOR.US) With Buy Rating, Announces Target Price $50
  Market Newswire · 2026/1/9
• Citi Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $50
  Market Newswire · 2026/9/10
• Rating change
  Vor Biopharma Price Target Maintained With a $31.00/Share by HC Wainwright & Co.
  Dow Jones · 2026/5/19
• Rating change
  H.C. Wainwright Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $31
  Market Newswire · 2026/8/12
• Rating change
  H.C. Wainwright Maintains Vor Biopharma(VOR.US) With Buy Rating, Cuts Target Price to $31
  Market Newswire · 2026/4/15
• Rating change
  Wedbush Maintains Vor Biopharma(VOR.US) With Hold Rating, Raises Target Price to $18
  Market Newswire · 2026/5/14

Headlines are aggregated automatically and are not independently verified or edited by our team.